Katja Rosenkranz

Katja Rosenkranz is currently a Partner at V-Bio Ventures and also serves as a Board Member at ExeVir and dualyx. Katja is a Member of the Board at AgomAb Therapeutics and previously held the position of Interim CEO at the same company. With a background in biochemistry and extensive experience in investment analysis and project management, Katja has also worked as a Senior Investment and Project Manager at Ascenion GmbH and as a Managing Director at Dr. Katja Rosenkranz & Rainer Friedl Gbr. Katja has a Ph.D. in Biochemistry from the Max Planck Institute of Neurobiology and holds an Executive MBA in Medical Devices & Healthcare Management from IBST.